Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Qizhen Shi MD, PhD

Qizhen Shi MD, PhD profile photo picture


Institution: Medical College of Wisconsin
Department: Pediatrics
Division: Hematology and Oncology - Pediatrics
Program: Oncology

Member of the Center for Immunology

I am willing to mentor a junior faculty member.
I am willing to collaborate on research projects.

Research Experience

  • Hemophilia A and hemophilia B, platelet-specific gene therapy, immune responses in gene therapy, FVIII immune responses.
  • Publications (70)

  • Blocking hemophilic arthropathy. (Shi Q, Weiler H) Blood 2022 05 05;139(18):2734-2735 PMID: 35511191 SCOPUS ID: 2-s2.0-85129525401 05/06/2022    
  • Association of Platelet Desialylation and Circulating Follicular Helper T Cells in Patients With Thrombocytopenia. (Chen Y, Luo L, Zheng Y, Zheng Q, Zhang N, Gan D, Yirga SK, Lin Z, Shi Q, Fu L, Hu J, Chen Y) Front Immunol 2022;13:810620 PMID: 35450072 PMCID: PMC9016750 SCOPUS ID: 2-s2.0-85128544465 04/23/2022    
  • A novel mouse model of type 2N VWD was developed by CRISPR/Cas9 gene editing and recapitulates human type 2N VWD. (Shi Q, Fahs SA, Mattson JG, Yu H, Perry CL, Morateck PA, Schroeder JA, Rapten J, Weiler H, Montgomery RR) Blood Adv 2022 05 10;6(9):2778-2790 PMID: 35015821 PMCID: PMC9092403 01/12/2022    
  • Thromboelastometry assessment of hemostatic properties in various murine models with coagulopathy and the effect of factor VIII therapeutics. (Schroeder JA, Kuether EA, Fang J, Jing W, Weiler H, Wilcox DA, Montgomery RR, Shi Q) J Thromb Haemost 2021 10;19(10):2417-2427 PMID: 34245090 PMCID: PMC8865566 SCOPUS ID: 2-s2.0-85111140299 07/11/2021    
  • Platelet gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of antigen-specific T cells (Li J, Chen J, Schroeder JA, Hu J, Williams CB, Shi Q) Molecular Therapy - Nucleic Acids 5 March 2021;23:719-730 SCOPUS ID: 2-s2.0-85099917698 03/05/2021       1 Citation
  • Platelet-targeted hyperfunctional FIX gene therapy for hemophilia B mice even with preexisting anti-FIX immunity. (Schroeder JA, Chen J, Chen Y, Cai Y, Yu H, Mattson JG, Monahan PE, Shi Q) Blood Adv 2021 03 09;5(5):1224-1238 PMID: 33646304 PMCID: PMC7948262 SCOPUS ID: 2-s2.0-85102965352 03/02/2021    
  • Platelet gene therapy induces robust immune tolerance even in a primed model via peripheral clonal deletion of antigen-specific T cells. (Li J, Chen J, Schroeder JA, Hu J, Williams CB, Shi Q) Mol Ther Nucleic Acids 2021 Mar 05;23:719-730 PMID: 33575117 PMCID: PMC7851450 SCOPUS ID: 2-s2.0-85099917698 02/13/2021       1 Citation
  • Platelet-Targeted FVIII Gene Therapy Restores Hemostasis and Induces Immune Tolerance for Hemophilia A. (Cai Y, Shi Q) Front Immunol 2020;11:964 PMID: 32595633 PMCID: PMC7303294 SCOPUS ID: 2-s2.0-85087185344 07/01/2020       2 Citations
  • In vivo enrichment of genetically manipulated platelets for murine hemophilia B gene therapy. (Chen Y, Schroeder JA, Gao C, Li J, Hu J, Shi Q) J Cell Physiol 2021 01;236(1):354-365 PMID: 32510630 PMCID: PMC7722216 SCOPUS ID: 2-s2.0-85086088416 06/09/2020    
  • Unexpected enhancement of FVIII immunogenicity by endothelial expression in lentivirus-transduced and transgenic mice. (Shi Q, Carman CV, Chen Y, Sage PT, Xue F, Liang XM, Gilbert GE) Blood Adv 2020 05 26;4(10):2272-2285 PMID: 32453842 PMCID: PMC7252558 SCOPUS ID: 2-s2.0-85086840336 05/27/2020    
  • A rat model of severe VWD by elimination of the VWF gene using CRISPR/Cas9. (Garcia J, Flood VH, Haberichter SL, Fahs SA, Mattson JG, Geurts AM, Zogg M, Weiler H, Shi Q, Montgomery RR) Res Pract Thromb Haemost 2020 Jan;4(1):64-71 PMID: 31989086 PMCID: PMC6971331 SCOPUS ID: 2-s2.0-85105291983 01/29/2020       1 Citation
  • The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression. (Shi Q, Mattson JG, Fahs SA, Geurts AM, Weiler H, Montgomery RR) Blood Adv 2020 01 14;4(1):55-65 PMID: 31899798 PMCID: PMC6960468 SCOPUS ID: 2-s2.0-85078174834 01/04/2020       8 Citations
  • Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. (Jing W, Chen J, Cai Y, Chen Y, Schroeder JA, Johnson BD, Cui W, Shi Q) Blood Adv 2019 10 22;3(20):3099-3110 PMID: 31648333 PMCID: PMC6849959 SCOPUS ID: 2-s2.0-85074935557 10/28/2019       11 Citations
  • Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. (Holstein SA, Al-Kadhimi Z, Costa LJ, Hahn T, Hari P, Hillengass J, Jacob A, Munshi NC, Oliva S, Pasquini MC, Shi Q, Stadtmauer EA, Waldvogel SL, McCarthy PL) Biol Blood Marrow Transplant 2020 01;26(1):e7-e15 PMID: 31526843 PMCID: PMC6942175 SCOPUS ID: 2-s2.0-85073734108 09/19/2019       9 Citations
  • Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice. (Gao C, Schroeder JA, Xue F, Jing W, Cai Y, Scheck A, Subramaniam S, Rao S, Weiler H, Czechowicz A, Shi Q) Blood Adv 2019 09 24;3(18):2700-2711 PMID: 31515232 PMCID: PMC6759737 SCOPUS ID: 2-s2.0-85072272107 09/14/2019       23 Citations
  • In vivo generated hematopoietic stem cells from genome edited induced pluripotent stem cells are functional in platelet-targeted gene therapy of murine hemophilia A. (Wang D, Zhang G, Gu J, Shao X, Dai Y, Li J, Pan X, Yao S, Xu A, Jin Y, Huang J, Shi Q, Zhu J, Xi X, Chen Z, Chen S) Haematologica 2020 04;105(4):e175-e179 PMID: 31296582 PMCID: PMC7109733 SCOPUS ID: 2-s2.0-85083225461 07/13/2019       8 Citations
  • The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity. (Chen J, Schroeder JA, Luo X, Montgomery RR, Shi Q) J Thromb Haemost 2019 03;17(3):449-459 PMID: 30609275 PMCID: PMC6397061 SCOPUS ID: 2-s2.0-85061041842 01/05/2019       10 Citations
  • Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells. (Luo X, Chen J, Schroeder JA, Allen KP, Baumgartner CK, Malarkannan S, Hu J, Williams CB, Shi Q) Front Immunol 2018;9:1950 PMID: 30237796 PMCID: PMC6136275 SCOPUS ID: 2-s2.0-85053056830 09/22/2018       9 Citations
  • Platelet-Targeted Gene Therapy for Hemophilia. (Shi Q) Mol Ther Methods Clin Dev 2018 Jun 15;9:100-108 PMID: 29520365 PMCID: PMC5842292 SCOPUS ID: 2-s2.0-85044867723 03/10/2018       22 Citations
  • The impact of von Willebrand factor on factor VIII memory immune responses. (Chen J, Schroeder JA, Luo X, Shi Q) Blood Adv 2017 Aug 22;1(19):1565-1574 PMID: 28920105 PMCID: PMC5600162 SCOPUS ID: 2-s2.0-85050807508 09/19/2017       6 Citations
  • Immune tolerance induced by platelet-targeted factor VIII gene therapy in hemophilia A mice is CD4 T cell mediated. (Chen Y, Luo X, Schroeder JA, Chen J, Baumgartner CK, Hu J, Shi Q) J Thromb Haemost 2017 10;15(10):1994-2004 PMID: 28799202 PMCID: PMC5630523 SCOPUS ID: 2-s2.0-85029226218 08/12/2017       20 Citations
  • Gene therapy (Shi Q, Montgomery RR) Platelets in Thrombotic and Non-Thrombotic Disorders: Pathophysiology, Pharmacology and Therapeutics: an Update 8 March 2017:1431-1445 SCOPUS ID: 2-s2.0-85055916604 03/08/2017    
  • TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice. (Haribhai D, Luo X, Chen J, Jia S, Shi L, Schroeder JA, Weiler H, Aster RH, Hessner MJ, Hu J, Williams CB, Shi Q) Blood Adv 2016 Dec 13;1(2):139-151 PMID: 28164173 PMCID: PMC5288643 02/07/2017    
  • Higher Fluid Balance Increases the Risk of Death From Sepsis: Results From a Large International Audit. (Sakr Y, Rubatto Birri PN, Kotfis K, Nanchal R, Shah B, Kluge S, Schroeder ME, Marshall JC, Vincent JL, Intensive Care Over Nations Investigators) Crit Care Med 2017 Mar;45(3):386-394 PMID: 27922878 SCOPUS ID: 2-s2.0-85002152455 12/07/2016       154 Citations
  • Targeting factor VIII expression to platelets for hemophilia A gene therapy does not induce an apparent thrombotic risk in mice. (Baumgartner CK, Mattson JG, Weiler H, Shi Q, Montgomery RR) J Thromb Haemost 2017 01;15(1):98-109 PMID: 27496751 PMCID: PMC5280575 SCOPUS ID: 2-s2.0-84997796223 08/09/2016       14 Citations
  • The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity. (Chen Y, Schroeder JA, Chen J, Luo X, Baumgartner CK, Montgomery RR, Hu J, Shi Q) Blood 2016 Mar 10;127(10):1346-54 PMID: 26668132 PMCID: PMC4786841 SCOPUS ID: 2-s2.0-84960904100 12/17/2015       14 Citations
  • Comparison of platelet-derived and plasma factor VIII efficacy using a novel native whole blood thrombin generation assay. (Baumgartner CK, Zhang G, Kuether EL, Weiler H, Shi Q, Montgomery RR) J Thromb Haemost 2015 Dec;13(12):2210-9 PMID: 26453193 PMCID: PMC4715732 SCOPUS ID: 2-s2.0-84958773657 10/11/2015       8 Citations
  • The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. (Shi Q, Schroeder JA, Kuether EL, Montgomery RR) J Thromb Haemost 2015 Jul;13(7):1301-9 PMID: 25955153 PMCID: PMC4496307 SCOPUS ID: 2-s2.0-84935446637 05/09/2015       16 Citations
  • Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome. (Kanaji S, Fahs SA, Ware J, Montgomery RR, Shi Q) J Thromb Haemost 2014 Oct;12(10):1726-32 PMID: 25066812 PMCID: PMC4194147 SCOPUS ID: 2-s2.0-84907878326 07/30/2014       6 Citations
  • Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development. (Mannucci PM, Shi Q, Bonanad S, Klamroth R) Haemophilia 2014 Sep;20 Suppl 6:2-16 PMID: 24975700 SCOPUS ID: 2-s2.0-84903212652 07/01/2014       12 Citations
  • In vivo enrichment of genetically manipulated platelets corrects the murine hemophilic phenotype and induces immune tolerance even using a low multiplicity of infection. (Schroeder JA, Chen Y, Fang J, Wilcox DA, Shi Q) J Thromb Haemost 2014 Aug;12(8):1283-93 PMID: 24931217 PMCID: PMC4127102 SCOPUS ID: 2-s2.0-84905667071 06/17/2014       27 Citations
  • A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. (Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR) Blood 2014 Jun 12;123(24):3706-13 PMID: 24705491 PMCID: PMC4055921 SCOPUS ID: 2-s2.0-84902594994 04/08/2014       108 Citations
  • Platelet Gene Therapy by Lentiviral Gene Delivery to Hematopoietic Stem Cells Restores Hemostasis and Induces Humoral Immune Tolerance in FIX(null) Mice. (Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q) Mol Ther 2014 Jan;22(1):169-177 PMID: 28141990 01/01/2014    
  • Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells. (Shi Q, Kuether EL, Chen Y, Schroeder JA, Fahs SA, Montgomery RR) Blood 2014 Jan 16;123(3):395-403 PMID: 24269957 PMCID: PMC3894495 SCOPUS ID: 2-s2.0-84897018747 11/26/2013       35 Citations
  • Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. (Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA) Nat Commun 2013;4:2773 PMID: 24253479 PMCID: PMC3868233 SCOPUS ID: 2-s2.0-84893419411 11/21/2013       82 Citations
  • Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. (Chen Y, Schroeder JA, Kuether EL, Zhang G, Shi Q) Mol Ther 2014 Jan;22(1):169-77 PMID: 24042561 PMCID: PMC3978792 SCOPUS ID: 2-s2.0-84891836194 09/18/2013       41 Citations
  • Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo. (Shi Q, Kuether EL, Schroeder JA, Perry CL, Fahs SA, Cox Gill J, Montgomery RR) J Thromb Haemost 2012 Nov;10(11):2328-37 PMID: 22908929 PMCID: PMC3670966 SCOPUS ID: 2-s2.0-84868144084 08/23/2012       15 Citations
  • Contribution of platelet vs. endothelial VWF to platelet adhesion and hemostasis. (Kanaji S, Fahs SA, Shi Q, Haberichter SL, Montgomery RR) J Thromb Haemost 2012 Aug;10(8):1646-52 PMID: 22642380 PMCID: PMC3419786 SCOPUS ID: 2-s2.0-84865237107 05/31/2012       81 Citations
  • Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. (Kuether EL, Schroeder JA, Fahs SA, Cooley BC, Chen Y, Montgomery RR, Wilcox DA, Shi Q) J Thromb Haemost 2012 Aug;10(8):1570-80 PMID: 22632092 PMCID: PMC3419807 SCOPUS ID: 2-s2.0-84864333652 05/29/2012       81 Citations
  • Platelet and endothelial expression of clotting factors for the treatment of hemophilia. (Montgomery RR, Shi Q) Thromb Res 2012 May;129 Suppl 2:S46-8 PMID: 22421106 PMCID: PMC3581347 SCOPUS ID: 2-s2.0-84859802515 03/17/2012       13 Citations
  • Intravascular recovery of VWF and FVIII following intraperitoneal injection and differences from intravenous and subcutaneous injection in mice. (Shi Q, Kuether EL, Schroeder JA, Fahs SA, Montgomery RR) Haemophilia 2012 Jul;18(4):639-46 PMID: 22221819 PMCID: PMC3323668 SCOPUS ID: 2-s2.0-84863193826 01/10/2012       16 Citations
  • Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy. (Kanaji S, Kuether EL, Fahs SA, Schroeder JA, Ware J, Montgomery RR, Shi Q) Mol Ther 2012 Mar;20(3):625-32 PMID: 22044935 PMCID: PMC3293608 SCOPUS ID: 2-s2.0-84857781525 11/03/2011       27 Citations
  • Alternative strategies for gene therapy of hemophilia. (Montgomery RR, Shi Q) Hematology Am Soc Hematol Educ Program 2010;2010:197-202 PMID: 21239794 PMCID: PMC3383974 SCOPUS ID: 2-s2.0-79955004711 01/18/2011       5 Citations
  • Platelets as delivery systems for disease treatments. (Shi Q, Montgomery RR) Adv Drug Deliv Rev 2010 Sep 30;62(12):1196-203 PMID: 20619307 PMCID: PMC2991519 SCOPUS ID: 2-s2.0-78649321428 07/14/2010       35 Citations
  • Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A. (Shi Q, Fahs SA, Kuether EL, Cooley BC, Weiler H, Montgomery RR) Blood 2010 Oct 21;116(16):3049-57 PMID: 20606161 PMCID: PMC2974610 SCOPUS ID: 2-s2.0-77958193310 07/08/2010       39 Citations
  • Factor IX ectopically expressed in platelets can be stored in alpha-granules and corrects the phenotype of hemophilia B mice. (Zhang G, Shi Q, Fahs SA, Kuether EL, Walsh CE, Montgomery RR) Blood 2010 Aug 26;116(8):1235-43 PMID: 20445020 PMCID: PMC2938234 SCOPUS ID: 2-s2.0-77955921912 05/07/2010       39 Citations
  • Syngeneic transplantation of hematopoietic stem cells that are genetically modified to express factor VIII in platelets restores hemostasis to hemophilia A mice with preexisting FVIII immunity. (Shi Q, Fahs SA, Wilcox DA, Kuether EL, Morateck PA, Mareno N, Weiler H, Montgomery RR) Blood 2008 Oct 01;112(7):2713-21 PMID: 18495954 PMCID: PMC2556608 SCOPUS ID: 2-s2.0-53449090226 05/23/2008       77 Citations
  • Lentivirus-mediated platelet-derived factor VIII gene therapy in murine haemophilia A. (Shi Q, Wilcox DA, Fahs SA, Fang J, Johnson BD, DU LM, Desai D, Montgomery RR) J Thromb Haemost 2007 Feb;5(2):352-61 PMID: 17269937 SCOPUS ID: 2-s2.0-33846453333 02/03/2007       106 Citations
  • Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. (Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC, Desai D, Morateck PA, Gorski J, Montgomery RR) J Clin Invest 2006 Jul;116(7):1974-82 PMID: 16823491 PMCID: PMC1483176 SCOPUS ID: 2-s2.0-33745864802 07/11/2006       138 Citations
  • Regulated release of VWF and FVIII and the biologic implications. (Haberichter SL, Shi Q, Montgomery RR) Pediatr Blood Cancer 2006 May 01;46(5):547-53 PMID: 16470522 SCOPUS ID: 2-s2.0-33645304827 02/14/2006       42 Citations
  • The biology of von Willebrand factor and factor VIII-regulated release. (Haberichter SL, Shi Q, and Montgomery RR.) Hematologica Reports 1 (6): 9-14. 06/02/2005    
  • The inhibition of bcr/abl antisense on chronic myelocyte leukemia (CML) primary cells. (Chen Y, Shi Q, Lu L, and Hu J.) Chinese Journal of Pathology 21 (2): 400-402. 02/16/2005    
  • Targeting platelet GPIbalpha transgene expression to human megakaryocytes and forming a complete complex with endogenous GPIbbeta and GPIX. (Shi Q, Wilcox DA, Morateck PA, Fahs SA, Kenny D, Montgomery RR) J Thromb Haemost 2004 Nov;2(11):1989-97 PMID: 15550031 SCOPUS ID: 2-s2.0-13244262627 11/20/2004       31 Citations
  • Induction of megakaryocytes to synthesize and store a releasable pool of human factor VIII. (Wilcox DA, Shi Q, Nurden P, Haberichter SL, Rosenberg JB, Johnson BD, Nurden AT, White GC 2nd, Montgomery RR) J Thromb Haemost 2003 Dec;1(12):2477-89 PMID: 14675082 SCOPUS ID: 2-s2.0-1542544992 12/17/2003       48 Citations
  • Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment. (Yarovoi HV, Kufrin D, Eslin DE, Thornton MA, Haberichter SL, Shi Q, Zhu H, Camire R, Fakharzadeh SS, Kowalska MA, Wilcox DA, Sachais BS, Montgomery RR, Poncz M) Blood 2003 Dec 01;102(12):4006-13 PMID: 12881300 SCOPUS ID: 2-s2.0-10744231807 07/26/2003       122 Citations
  • Expression of human factor VIII under control of the platelet-specific alphaIIb promoter in megakaryocytic cell line as well as storage together with VWF. (Shi Q, Wilcox DA, Fahs SA, Kroner PA, Montgomery RR) Mol Genet Metab 2003 May;79(1):25-33 PMID: 12765843 SCOPUS ID: 2-s2.0-0038522536 05/27/2003       41 Citations
  • Detection and Analysis of P16 Gene Deletion in Acute Lymphocytic Leukemia. (Chen Y, Yang Y, Lu L, and Shi Q.) Chinese New Medicine 3(5): 405-406. 03/13/2002    
  • The effect on K562 cells by combining bcr/abl and c-myb antisense oligonucleotides. (Shi Q, and Lu L.) Chinese Journal of Oncology Biotherapy 7 (4): 251-254. 04/30/2001    
  • Gene expression inhibitory and apoptosis of K562 cells by bcr/abl antisense oligonucleotides. (Shi Q, Lu L, Chen Y, and Hu J.) Chinese Journal of Applied Physiology 17 (3): 213-216. 03/03/2001    
  • The efficacy of alky-lysophospholipid ET-18- OCH3 on K562 cells. (Shi Q, Huang H, Chen Z, and Lu L.) Journal of Cell Biology 23 (2): 98-102. 02/05/2001    
  • The effect of antisense bcr-abl oligonucleotides on the cell growth of K562 cells. (Shi Q, Lu L, Hu J, Yang Y, and Chen Y.) Chinese Journal of Pathophysiology 16 (4): 342-346. 08/28/2000    
  • The expression of Wt1 gene in hematopoietic malignant disease and its relation to prognosis. (Shi Q, and Lu L, Zhan R, Hu J.) Chinese Journal of Medical Genetics 17 (4): 301-302. 04/10/2000    
  • The efficacy of c-myb antisense phosphorothioate oligonucleotides on K562 cells. (Shi Q, and Lu L.) Chinese Journal of Hematology 20 (7): 371-372. 07/05/1999    
  • Study of Bcl I and Hind III polymorphisms in the factor VIII gene by PCR. (Shi Q, Lu L, and Zhang X.) Chinese Journal of Birth Health and Heredity 5 (6): 21-23. 06/13/1997    
  • Gene therapy of chronic myelogenous leukemia by use of antisense technology. (Shi Q, and Lu L.) Journal of Fujian Medical University 31 (4): 458-460. 04/10/1997    
  • Chronic myelogenous leukemia complicated with malignant lymphoma. (Shi, Q,* Lu L, Chen Z, and Huang S.) Chinese Journal of Clinical Oncology and Rehabilitation 3 (4): 56-59. 04/16/1996    
  • Diagnosis using Genomic Amplification with Transcripts Sequencing (GAWTS). (Liu J, Xiang H, Liu L, Zhou H, Zhang J, Shi Q, Chen H, Zhen S, and Sommer SS.) Chinese Journal of Medicine 75 (10): 599-601. 10/06/1995    
  • Genetic diagnosis of hemophilic carriers by PCR/RFLP. (Shi Q, Lu L, and Zhang X.) Chinese Journal of Medical Genetics 12 (2): 107-108. 02/18/1995    
  • Study of gene mutation of FIX B patients from China. (Liu J, Chen H, and Zhang J, Erica V, Yi H, Zheng S, Shi Q, Wang H, Sommer SS.) High Technology Letters 8:29-32. 11/06/1994    
  • Genetic diagnosis of hemophilia A using Polymerase Chain Reaction. (Shi Q, Lu L, and Zhang X.) Transfusion and Hematology 17 (4): 202-205. 08/12/1994    
  • Last update: 06/10/2022